Estrogen receptor

Estrogen receptor biology centers on ERα/ESR1 and ERβ/ESR2, nuclear transcription factors that regulate complex physiological processes^[1]. In mammary tissue, 17β-estradiol controls post-natal mammary gland development through ERα, which coordinates classical nuclear “genomic” and membrane “non-genomic” signaling^[2]. Mechanistically, these pathways regulate mammary morphogenesis, luminal cell-lineage features, and hormone-dependent breast cancer models^[2]. In disease models, ERα is critical for breast cancer progression and remains a central therapeutic target in hormone-dependent breast cancers^[2]. Compared with ERβ, ERα differs in ligand-binding specificity and transcript tissue distribution, supporting isoform-selective estrogen receptor research design^[3]. For experimental applications, ER modulators include subtype-selective ligands with potential clinical relevance across cancer, metabolic disease, cardiovascular disease, neurodegeneration, inflammation, and osteoporosis^[1]. Fulvestrant, a selective estrogen receptor downregulator, shows antitumor activity in preclinical breast cancer models and enables studies of ERα degrader activity^[4].